Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

Stefano Luminari, Elda Viel, Andrés José Maria Ferreri, Francesco Zaja, Emanuela Chimienti, Gerardo Musuraca, Alessandra Tucci, Monica Balzarotti, Monica Tani, Francesca Salvi, Emanuela A. Pesce, Angela Ferrari, Anna M. Liberati, Antonio Spadea, Dario Marino, Maria Bruno-Ventre, Stefano Volpetti, Chiara Bottelli, Elena Ravaioli, Francesco MerliMichele Spina

Research output: Contribution to journalArticlepeer-review

Abstract

The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of “R-COMP” combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF
Original languageEnglish
Pages (from-to)68-75
Number of pages8
JournalHematological Oncology
Volume36
Issue number1
DOIs
Publication statusE-pub ahead of print - May 17 2017

Keywords

  • cardiotoxicity
  • diffuse large B-cell lymphoma
  • non-pegylated liposomal doxorubicin

Fingerprint Dive into the research topics of 'Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi'. Together they form a unique fingerprint.

Cite this